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Abstract
Public health response to large scale chemical emergencies presents logistical challenges for 
sample collection, transport, and analysis. Diagnostic methods used to identify and determine 
exposure to chemical warfare agents, toxins, and poisons traditionally involve blood collection by 
phlebotomists, cold transport of biomedical samples, and costly sample preparation techniques. 
Use of dried blood spots, which consist of dried blood on an FDA-approved substrate, can increase 
analyte stability, decrease infection hazard for those handling samples, greatly reduce the cost of 
shipping/storing samples by removing the need for refrigeration and cold chain transportation, and 
be self-prepared by potentially exposed individuals using a simple finger prick and blood spot 
compatible paper. Our laboratory has developed clinical assays to detect human exposures to nerve 
agents through the analysis of specific protein adducts and metabolites, for which a simple 
extraction from a dried blood spot is sufficient for removing matrix interferents and attaining 
sensitivities on par with traditional sampling methods. The use of dried blood spots can bridge the 
gap between the laboratory and the field allowing for large scale sample collection with minimal 
impact on hospital resources while maintaining sensitivity, specificity, traceability, and quality 
requirements for both clinical and forensic applications.
INTRODUCTION
Chemical emergencies have the potential to impact large numbers of persons, whether 
directly through illness and death, or indirectly through low dose exposures and the worried 
well. Public health response following a chemical release, including intentional, 
unintentional, and natural occurrences, consists of documenting the people injured and 
exposed as well as the geographical extent of the event. This information supports 
emergency response efforts by identifying the chemical agent which is crucial for mitigating 
additional exposures, including secondary exposures to medical personnel, and preparing for 
future events through materials distribution1. Although a significant amount of information 
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regarding individuals treated medically will be gathered post treatment, there is still a need 
to identify those with minimal symptoms and even no symptomology, who still may have 
been exposed. A clinical assay can be used to capture this information as long as the blood 
or urine is appropriately collected within a time window following exposure that is sufficient 
for specific biomarkers to be present.
Although fieldable assays are available for clinical sample analysis, there are advantages to 
rapidly collecting and transporting samples to established laboratories for analysis. The 
infrastructure within a clinical laboratory is designed to address sample chain of custody, 
ensure the safety and security of the personal information required with collection of clinical 
specimens, and maintain strict adherence to sample traceability ensuring the correct result is 
connected with the accompanying epidemiological data2. The controlled and regulated 
environment of the laboratory also ensures quality of the results while the isolation of the 
laboratory minimizes the impact of the chaos from the event on laboratory activities.
Traditional clinical sample collection of blood requires a trained phlebotomist to capture the 
sample and specific storage conditions to maintain the integrity of the blood sample (e.g. 
preventing clotting or hemolysis)3. Additionally, there are safety concerns of blood borne 
pathogens which have the potential to infect those handling contaminated samples, whether 
during collection, shipping, aliquoting, or analysis4. These issues further complicate 
transportation of samples requiring additional safe guards and cold transport to ensure safe 
delivery of viable samples. Dried blood spots (DBS) are an alternative matrix that addresses 
all of these issues and ultimately can reduce the requirements for trained personnel to collect 
samples5, reduce the materials needed for sample collection, reduce transportation costs6, 
and minimize potential blood borne pathogen exposures.
Clinical methods have relied upon dried blood spots for years, particularly in the field of 
newborn screening7, as well as epidemiological8 and environmental population studies9. 
Dried blood samples can be collected through a variety of mechanisms: samples can be 
directly spotted from a finger prick onto a DBS card, measured prior to spotting onto the 
DBS card using a pipette or capillary, or drawn from a finger into a microsampler device 
(Figure 1)10. The simplest means of sample collection, the lance and spot approach, presents 
challenges for quantitative analysis primarily due to the hematocrit of the blood. The 
hematocrit, or the measure of blood cells, impacts the spread of the blood prior to drying, 
subsequently resulting in different sample volumes from the same spot size. This issue can 
be addressed by analysis of a whole spot with a known volume11. Measured spots can be 
self-created using a capillary to deliver a set volume or in a laboratory setting using a 
pipette. This adds another level of complexity to the sample collection, which is undesirable 
for emergency response; however, a controlled volume spot does permit quantitation without 
any need for correction. In the event that a spot of undetermined volume is received, an 
analytical correction using a measure of protein content from the same spot can be used to 
attain accurate quantitative measurements12. However, this approach requires additional 
testing of each sample for both the analyte of interest and protein content and confirmation 
of a direct correlation between the protein content and the analyte concentration. Another 
alternative is a microsampler, which consistently draws 10 μL of blood regardless of 
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hematocrit10. This device enables self-sampling, with minimal equipment, while 
maintaining a constant volume for each sample necessary for quantitation.
Additional advantages for DBS may be the reduction in sample preparation steps and costs. 
For some analyses, the extraction of the analytes from the DBS can replace a previous solid 
phase extraction or liquid-liquid extraction step. Furthermore, extraction from the DBS is 
simple, straightforward, and requires minimal solvents, reducing time to results and overall 
costs of analysis.
To test the efficacy of dried samples for exposures assessment, three assays used to identify 
human exposure to nerve agents were evaluated. As cholinesterase inhibitors, a measure of 
cholinesterase activity serves as a non-specific test of exposure and can be measured from 
butyrylcholinesterase (BChE) in plasma, serum, or whole blood13. More specific methods 
include the identification of BChE bound nerve agents14 and hydrolyzed nerve agents, often 
referred to as organophosphorus nerve agent (OPNA) metabolites15. Typical sample 
preparation involved protein precipitation followed by specific chemical extraction (solid 
phase extraction) or biological recognition (antibody capture) of the analytes of interest to 
isolate the analyte from the matrix. Subsequent chromatographic separation and tandem 
mass spectrometry were used for identification and quantitation.
This study evaluated multiple dried sampling approaches, including dried blood spots and 
microsamplers for the determination of human exposure to nerve agents. Specific 
biomarkers evaluated were OPNA metabolites and OPNA adducts to BChE. BChE activity, 
a determination of unadducted BChE, was also evaluated for efficacy in DBS, including a 
correction of concentration to the total protein content. Precision and accuracy, including 
comparability to traditional methods, were determined along with an assessment of stability 
for select analytes with known degradation issues.
METHODOLOGY
Preparation of calibrators and controls
Whole blood and serum, purchased from Tennessee Blood Services (Memphis, TN) were 
used as a control sample for both BChE activity and BChE. This pooled blood was also 
fortified to prepare controls and calibrators for OPNA metabolites. Metabolites of GB 
(sarin), GD (soman), GF (cyclosarin), VX, and VR (Russian VX) purchased from Cerilliant 
(Round Rock, TX) were diluted in water and spiked directly into pooled blood. Calibrators 
were volumetrically prepared at concentrations ranging from 5 – 500 ng/mL with control 
samples prepared at 30 and 250 ng/mL. Control samples for GB-BChE, and VX-BChE were 
prepared by spiking live agent (GB and VX) into serum as described previously14.
Calibrators for BChE activity were prepared from recombinant human BChE (Protexia) in 
filtered 4% nonfat dried milk at concentrations ranging from 0.05 – 6.4 U/mL14. Calibrators 
for GB-BChE, and VX-BChE were prepared from the synthetic peptides (TNO, Rijswik, the 
Netherlands) at concentrations ranging from 1–250 ng/mL14, 16.
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Spots were prepared by pipetting 5, 40, or 300 μL onto preprinted Whatman 903 protein 
saver cards (Fisher Scientific, Waltham, MA) and allowed to dry at room temperature for a 
minimum of 2 hours prior to storage with desiccant or humidity sponge (VWR International, 
Radnor, PA) in a zipper close bag at a minimum temperature of −70 C. Mitra™ 
microsamplers (Neoteryx, Torrance, CA) were prepared by following the manufacturer’s 
instructions, allowing for a minimum 2 hour drying time before storage with desiccant or 
humidity sponge in a zipper close bag at a minimum temperature of −70 C.
Sample preparation of dried samples
Dried blood spots containing OPNA metabolites (including calibrators and controls) were 
prepared for analysis by punching (using a standard 0.25 in single-hole punch) the entire 5 
μL spot from the card or removing the microsampler tip from the holder and placing the 
punch/tip into a 96-well plate along with 25 μL of 23.8 ng/mL isotopically labeled internal 
standard (Cerilliant, Round Rock, TX) and 250 μL of HPLC-grade methanol (Tedia, 
Fairfield, OH). The plate was sealed with adhesive foil and mixed for 10 minutes using a 
ThermoLab Systems Wellmix (Hudson, NH). The supernatant was transferred into a clean 
96-well plate and concentrated to dryness in an UltraVap (Porvair Sciences, Leatherhead, 
U.K) at 70 °C using a flowrate of 70 L/min. The residue was then reconstituted and mixed 
thoroughly with 100 μL of 5% water in HPLC-Grade acetonitrile (Tedia, Fairfield, OH).
BChE adducts were eluted from microsamplers using 100 μL of HPLC-grade water (Tedia, 
Fairfield, OH). The supernatant was then mixed with magnetic beads coated with BChE 
specific antibodies. The beads were removed from the supernatant, washed, and incubated 
into buffer and enzyme to digest the protein. The digested samples were filtered, 
concentrated to dryness, and reconstituted in 75 μL of 0.6% formic acid.
DBS and microsamplers were reconstituted in 100 μL of HPLC-grade water for evaluation 
of BChE activity and total protein content.
LC-MS/MS instrumental analysis
For the OPNA metabolites, a volume of 5 μL of each sample was injected onto an Agilent 
1290 LC System (Santa Clara, CA) and separated isocratically using a Waters (Milford, 
MA) HILIC HPLC column (3 μm, 2.1 × 50 mm) with 14% 20 mM ammonium acetate 
(Fluka, St. Louis, MO) and 86% acetonitrile as the mobile phase at a flow rate of 500 μL/
min. Analytes were detected using turbo ion electrospray tandem mass spectrometry on a 
Sciex 6500 triple quadrupole mass spectrometer (Foster City, CA) in negative ion mode as 
described previously11.
The prepared BChE adduct samples and peptide calibrators were similarly separated and 
detected using reverse phase C18 chromatography coupled to tandem mass spectrometry as 
described previously14, 16.
Calibration curves for BChE adducts and OPNA metabolites were prepared relative to 
internal standard response with 1/x weighting. All calibration curves met the r2 criteria of 
0.990 for acceptance. Methods were characterized for precision and accuracy by an 
evaluation of quality control samples analyzed with respect to a single calibration curve, not 
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exceeding two runs per day. Between 7 and 20 replicates were used to characterize each 
method or sample type. Recoveries were determined by comparing fortified matrix samples 
extracted to extracted matrix samples post-spiked at the same concentration. Matrix effects 
were determined by comparing solvent samples to extracted matrix samples post-spiked at 
the same concentration.
Activity and protein measurements
BChE activity measurements were performed using a modified Ellman assay, detailed 
previously14. Calibrators and controls were diluted 1:5 with blocking solution in a protein 
LoBind plate and then 10 μL were mixed with phosphate buffer and dithiobis-nitrobenzoic 
acid (EQM Research, Cincinnati, OH). The plate was placed on a preheated BioTek Synergy 
H4Microplate Reader (Winooski, VT) and allowed to mix. After 10 min, 20 μL of 20.0 mM 
butyrylthiocholine was added to each well, mixed for 10 s, and measured at 412 nm for 
plasm/serum samples and 430 nm for blood samples. This cycle of shaking and 
measurements was repeated for 20 min. The change in absorbance was plotted over time and 
used to determine a slope for each well. A linear least-squares regression with 1/y weighting 
was used to quantify activity via a calibration curve of standards.
Total protein content was determined using a Pierce micro BCA (bicinchoninic acid) protein 
assay kit (VWR International, Radnor, PA) performed in triplicate according to the 
manufacturer’s instructions and documented previously14. Simply, a calibration curve was 
created using the provided standard from 5 – 200 μg/mL. Calibrators and samples were 
diluted 1:1000. BCA working reagent (100 μL) was added to 100 μL of sample, mixed, and 
incubated for 2 h at 37 °C. The absorbance at 562 nm was measured and a second degree 
polynomial regression with 1/y weighting was used to quantify total protein via a calibration 
curve of standards.
DATA AND RESULTS
Previously, we developed an analytical panel of biomarkers to identify human exposures to 
organophosphorus nerve agents using plasma or serum16–18. This broad sweeping approach 
accommodated identification of low dose exposures, but required the appropriate handling 
and storage of whole blood, plasma, or serum to obtain a viable sample for analysis. To 
address the challenges of whole blood sample collection, shipping, and storage, dried blood 
samples were evaluated using each of the methods referenced to determine if this sample 
source was amenable for these analyses.
To evaluate DBS for detection and quantitation of OPNA metabolites, spots of 5 μL were 
prepared. This small DBS permitted a single punch to capture the entire spot, ensuring the 
analysis of a known volume, while minimizing the impact of hematocrit. OPNA metabolites 
were extracted from the dried sample using methanol coupled with a small volume of 
aqueous internal standard; this combination achieved ~100% recovery of all analytes from 
the DBS with a short incubation period at room temperature. The direct extraction of OPNA 
metabolites from DBS resulted in minimal matrix effects (−2.27–2.24%), eliminating the 
need for additional sample preparation such as solid phase extraction as was necessary for 
the wet whole blood, plasma, and serum samples11, 17. Precision ranged from 6.17–14.2% 
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and accuracy ranged from 93.6–111% for two quality control samples at 30 and 250 ng/mL 
assessed over a period of 66 days, with a maximum of two analyses per day. Furthermore, 
the analyte peak areas from the DBS were consistent with equivalent concentrations injected 
on column from the traditional whole blood sample preparation [Figure 2]. This further 
supports the DBS extraction as an efficient and effective means of sample preparation for 
this analysis. The reportable range for the detection of OPNA metabolites from DBS was 
sufficient to identify exposures; however, the reduced sample volume (5 μL) resulted in an 
order of magnitude less sensitivity than previously achieved with wet samples11. Given the 
excellent reduction in matrix effects noted for these compounds, increasing the initial dried 
sample volume may alleviate these sensitivity issues.
Larger volume dried blood spots (40 μL) were prepared, eluted, and analyzed for BChE 
activity. First, it was confirmed that the activity of the BChE protein was retained through 
the drying and elution process. However, initial experiments identified a disparity between 
the dried spot results from whole blood, plasma, and serum when compared to the unspotted 
matrix matched control sample. When the dilution differences were accounted for, the final 
BChE activity recovered was ~80% for whole blood and >90% for plasma and serum. To 
address this bias, the measured BChE activity was correlated to the total protein content for 
each sample. This normalization reduced the disparity between spotted and unspotted 
samples of different dilutions when water was used as the elution solution.
Multiple individual punches from a 300 μL DBS were measured for BChE activity. It was 
noted that there was some variance depending on the location of the punch from the DBS; 
this effect was particularly significant for plasma and serum spots. When the normalization 
to the total protein content for each spot was applied, the variance between the corrected 
results diminished substantially. This further confirms reporting relative to protein content 
provides an accurate result for BChE activity in spots of unknown volume as well as any 
location within a spot, which may impact the percent of protein content.
The preparation of a DBS without a known volume is simple for collection, but still presents 
challenges from a laboratory perspective by requiring additional testing to assure accurate 
results. Another possibility that addresses a known volume with a simple sample collection 
is a microsampler. This device uses volumetric absorptive microsampling (VAMS™) 
technology that has consistently demonstrated a draw of 10 μL of whole blood, regardless of 
hematocrit. These samplers wick the blood without the need for additional volume 
measurement and can be directly collected from a finger prick. Microsamplers were 
evaluated for use in the analysis of OPNA metabolites, BChE activity, and BChE adducts, to 
provide a suite of analytical methods applicable to identification of nerve agent exposures.
OPNA metabolites were extracted from the microsamplers using methanol as previously 
completed with DBS. Since BChE activity and BChE-adducts are measurements of the same 
protein, elution with water, established with DBS for BChE activity, was applied to the 
microsamplers. The BChE adducts were further prepared for analysis through BChE 
antibody capture followed by an enzyme digestion. The resulting nonapeptide was compared 
to synthetic nonapeptide calibrators for quantitation. All three methods resulted in precision 
<14% and accuracy from 80.0–108% as shown in Figure 4. These analytical results indicate 
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that the use microsamplers are a viable alternative to DBS with high ease of sample 
collection needed for use during an exposure event.
Dried samples offer many advantages, including simplified sample collection and analysis, 
while maintaining the needed precision, accuracy, sensitivity, and ease of use. Furthermore, 
the shipping and storage of dried samples only requires minimal space and few regulated 
conditions as long as the DBS or microsamplers are maintained in a cool, dry place. With 
proper storage, dried samples may also provide increased analyte stability. BChE adducts, 
documented to have degradation issues16, were assessed for stabilization within dried spots.
Analyte stability of GB-BChE and VX-BChE was evaluated using fortified serum samples 
as well as dried versions of the same fortified samples at 4, 22, and 37 °C. The control for 
this experiment was maintained at −80 °C for the duration of the experiment, which was 
conducted isochronously. Over the period of 14 days, the dried serum samples were more 
resilient to loss of the GB or VX inhibitor from the BChE protein when compared to the 
samples in solution (Figure 5). At the highest temperature (37 °C) the unspotted serum 
samples exhibited a decrease in GB-BChE and VX-BChE proteins with approximate 85% 
losses determined. However, the dried serum samples exhibited no trend that would indicate 
the loss GB-BChE or VX-BChE. These results support the use of dried samples as a 
mechanism to minimize stability issues for these analytes.
CONCLUSIONS
Clinical methods have been developed and evaluated that perform comparably in plasma or 
serum and dried whole blood spots as well as microsamplers. With these results, dried 
samples can be used as an effective tool for capturing epidemiological samples in the event 
of a chemical exposure. They resolve many issues that may impede the collection of samples 
from potentially exposed persons, including cumbersome sample measurement and 
collection as well as biological hazards and cold shipment and storage concerns. 
Furthermore, the simplification of sample preparation with sufficient sensitivity for exposure 
identification supports the use of dried blood samples. As additional response assays are 
developed which measure biomarkers of exposure, DBS and microsamplers can further be 
incorporated into public health response, taking advantage of the many benefits.
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Potential sampling mechanisms for dried spots relative to volume control and sample 
collection.
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Comparison of GB (sarin) metabolite chromatograms from (A) dried blood spot (5 μL 
sample) and (B) unspotted serum (50 μL sample) with commensurate injection amounts.
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Sampling location within dried spots (A) to determine variance of butyrylcholinesterase 
(BChE) activity across individual dried blood, plasma, and serum spots (B) and the 
reduction of variance between individual spot samples through normalization of the BChE 
activity to total protein content (C)14.
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Measured accuracy and precision (represented as error bars) of GB and VX nerve agent 
biomarkers in unspotted whole blood, dried blood spots, and microsamplers.
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Stability of butyrylcholinesterase bound VX (VX-BChE) relative to total protein content in 
dried serum spots and unspotted serum stored at 22 and 37 °C for 14 days14.
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